Y Glim M 2mg/500mg Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, formulated as a sustained-release tablet. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The sustained-release formulation allows for gradual drug release, improving patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Y Glim M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity. It is essential to monitor blood glucose levels regularly to adjust dosage and prevent hypoglycemia. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular conditions. This combination therapy offers a synergistic approach to glycemic control, addressing multiple pathophysiological aspects of type 2 diabetes, thereby improving overall metabolic outcomes.